Innate Pharma
IPHA
9 hedge funds and large institutions have $179K invested in Innate Pharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.08% less ownership
Funds ownership: 0.19% → 0.11% (-0.08%)
10% less funds holding
Funds holding: 10 → 9 (-1)
37% less capital invested
Capital invested by funds: $282K → $179K (-$103K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$15.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.77K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
+$2.48K |
| 4 |
PS
Principal Securities
Des Moines,
Iowa
|
+$91 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ETC
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
-$112K |
| 2 |
Millennium Management
New York
|
-$7.44K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.18K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$416 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $93K | +$15.6K | +7,700 | +18% |
|
|
2
Citadel Advisors
Miami,
Florida
| $46.6K | +$4.77K | +2,350 | +10% |
|
|
3
Millennium Management
New York
| $20.4K | -$7.44K | -3,665 | -24% |
|
|
4
UBS Group
Zurich,
Switzerland
| $10.8K | -$6.18K | -3,044 | -34% |
|
|
GI
5
GAMMA Investing
Foster City,
California
| $6.27K | +$2.48K | +1,223 | +55% |
|
|
6
RhumbLine Advisers
Boston,
Massachusetts
| $822 | -$416 | -205 | -30% |
|
7
Barclays
London,
United Kingdom
| $557 | – | – | – |
|
8
Optiver Holding
Amsterdam,
Netherlands
| $177 | – | – | – |
|
|
PS
9
Principal Securities
Des Moines,
Iowa
| $82 | +$91 | +45 | New |
|
|
ETC
10
Exchange Traded Concepts
Oklahoma City,
Oklahoma
| – | -$112K | -62,752 | Closed |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| – | -$5 | -3 | Closed |
|
IPHA Hedge Fund Activity: Q2 2025 in Review
9 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2025, worth a combined $179K — down 37% from $282K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of IPHA and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $15.6K. The largest seller was Exchange Traded Concepts, exiting entirely with an estimated $112K sold.
- 9 institutional investors held Innate Pharma (IPHA) as of Q2 2025, down from 10 in Q1 2025.
- Funds reported $179K of Innate Pharma stock for Q2 2025, down 37% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q2 2025 and 2 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q2 2025 was Morgan Stanley, an estimated $15.6K added.
- The largest Innate Pharma seller in Q2 2025 was Exchange Traded Concepts, an estimated $112K sold.
Based on aggregated 13F filings for Q2 2025.